Bone disease after renal transplantation

Nature Reviews Nephrology

Volumn 6, Issue 1, 2010, Pages 32-40

  Malluche, Hartmut H ^a   Monier Faugere, Marie Claude ^a   Herberth, Johann ^a  

^a UNIVERSITY OF KENTUCKY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CALCITRIOL; CYCLOSPORIN A; EVEROLIMUS; GLUCOCORTICOID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PAMIDRONIC ACID; PARATHYROID HORMONE[1-34]; RAPAMYCIN; TACROLIMUS; VITAMIN D;

BONE DENSITY; BONE DISEASE; BONE METABOLISM; BONE TURNOVER; CALCIUM METABOLISM; CARDIOVASCULAR DISEASE; FRACTURE; GRAFT SURVIVAL; HUMAN; KIDNEY FUNCTION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; NONHUMAN; OSTEOLYSIS; OSTEOPOROSIS; OUTCOME ASSESSMENT; PHOSPHATE METABOLISM; PRIORITY JOURNAL; RENAL OSTEODYSTROPHY; REVIEW; RISK FACTOR;

ANIMALS; HUMANS; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; POSTOPERATIVE COMPLICATIONS; RENAL OSTEODYSTROPHY; RISK FACTORS;

EID: 74849121654     PISSN: 17595061     EISSN: 1759507X     Source Type: Journal    
DOI: 10.1038/nrneph.2009.192     Document Type: Review

References (114)

1. Nishikawa, K. & Terasaki, P. I. Annual trends and triple therapy-1991-2000. Clin. Transpl. 247-269 (2001).
2. Marcen, R. & Teruel, J. L. Patient outcomes after kidney allograft loss. Transplant Rev. (Orlando) 22, 62-72 (2008).
3. Malluche, H. H. & Faugere, M. C. Atlas of Mineralized Bone Histology (Karger, New York, 1986).
4. Hruska, K. A. & Teitelbaum, S. L. Renal osteodystrophy. N. Engl. J. Med. 333, 166-174 (1995).
5. wang, M. et al. Relationship between intact 1-84 parathyroid hormone and bone histomorphometric parameters in dialysis patients without aluminum toxicity. Am. J. Kidney Dis. 26, 836-844 (1995).
6. Parfitt, A. M. Bone histomorphometry: proposed system for standardization of nomenclature, symbols, and units. Calcif. Tissue Int. 42, 284-286 (1988).
7. Malluche, H. H. & Monier-Faugere, M. C. Renal osteodystrophy: what's in a name? Presentation of a clinically useful new model to interpret bone histologic findings. Clin. Nephrol. 65, 235-242 (2006).
8. Moe, S. et al. Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 69, 1945-1953 (2006).
9. Malluche, H., Lee, J., wang, G., Herberth, J. & Faugere, M. C. Usefulness of the new TMv classification of renal osteodystrophy. J. Am. Soc. Nephrol. 19, 38A (2008).
10. Kurz, P. et al. evidence for abnormal calcium homeostasis in patients with adynamic bone disease. Kidney Int. 46, 855-861 (1994).
11. Bell, K. L. et al. A novel mechanism for induction of increased cortical porosity in cases of intracapsular hip fracture. Bone 27, 297-304 (2000).
12. Greenspan, S. L., Beck, T. J., Resnick, N. M., Bhattacharya, R. & Parker, R. A. effect of hormone replacement, alendronate, or combination therapy on hip structural geometry: a 3-year, double-blind, placebo-controlled clinical trial. J. Bone Miner. Res. 20, 1525-1532 (2005).
13. London, G. M. et al. Arterial calcifications and bone histomorphometry in end-stage renal disease. J. Am. Soc. Nephrol. 15, 1943-1951 (2004).
14. Adragao, T. et al. Low bone volume-a risk factor for coronary calcifications in hemodialysis patients. Clin. J. Am. Soc. Nephrol. 4, 450-455 (2009).
15. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int. Suppl. S1-S130 (2009).
16. Bordier, P. et al. vitamin D metabolites and bone mineralization in man. J. Clin. Endocrinol. Metab. 46, 284-294 (1978).
17. Malluche, H. H., Goldstein, D. A. & Massry, S. G. Osteomalacia and hyperparathyroid bone disease in patients with nephrotic syndrome. J. Clin. Invest. 63, 494-500 (1979).
18. wolpaw, T. et al. Factors influencing vertebral bone density after renal transplantation. Transplantation 58, 1186-1189 (1994).
19. Briner, v. A. et al. Prevention of cancellous bone loss but persistence of renal bone disease despite normal 1,25 vitamin D levels two years after kidney transplantation. Transplantation 59, 1393-1400 (1995).
20. Grotz, w. H. et al. Bone loss after kidney transplantation: a longitudinal study in 115 graft recipients. Nephrol. Dial. Transplant. 10, 2096-2100 (1995).
21. Grotz, w. H. et al. Bone mineral density after kidney transplantation. A cross-sectional study in 190 graft recipients up to 20 years after transplantation. Transplantation 59, 982-986 (1995).
22. Monier-Faugere, M. C., Mawad, H., Qi, Q., Friedler, R. M. & Malluche, H. H. High prevalence of low bone turnover and occurrence of osteomalacia after kidney transplantation. J. Am. Soc. Nephrol. 11, 1093-1099 (2000).
23. Julian, B. A. et al. Rapid loss of vertebral mineral density after renal transplantation. N. Engl. J. Med. 325, 544-550 (1991).
24. Rojas, e. et al. The pathogenesis of osteodystrophy after renal transplantation as detected by early alterations in bone remodeling. Kidney Int. 63, 1915-1923 (2003).
25. Canalis, e. & Delany, A. M. Mechanisms of glucocorticoid action in bone. Ann. NY Acad. Sci. 966, 73-81 (2002).
26. weinstein, R. S., Jilka, R. L., Parfitt, A. M. & Manolagas, S. C. Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone. J. Clin. Invest. 102, 274-282 (1998).
27. Suzuki, Y., Ichikawa, Y., Saito, e. & Homma, M. Importance of increased urinary calcium excretion in the development of secondary hyperparathyroidism of patients under glucocorticoid therapy. Metabolism 32, 151-156 (1983).
28. Canalis, e., Mazziotti, G., Giustina, A. & Bilezikian, J. P. Glucocorticoid-induced osteoporosis: pathophysiology and therapy. Osteoporos. Int. 18, 1319-1328 (2007).
29. Sakakura, M., Takebe, K. & Nakagawa, S. Inhibition of luteinizing hormone secretion induced by synthetic LRH by long-term treatment with glucocorticoids in human subjects. J. Clin. Endocrinol. Metab. 40, 774-779 (1975).
30. Brandenburg, v. M. et al. Lumbar bone mineral density in very long-term renal transplant recipients: impact of circulating sex hormones. Osteoporos. Int. 16, 1611-1620 (2005).
31. O'Shaughnessy, e. A., Dahl, D. C., Smith, C. L. & Kasiske, B. L. Risk factors for fractures in kidney transplantation. Transplantation 74, 362-366 (2002).
32. vautour, L. M. et al. Long-term fracture risk following renal transplantation: a populationbased study. Osteoporos. Int. 15, 160-167 (2004).
33. Ugur, A. et al. Osteoporosis after renal transplantation: single center experience. Transplantation 71, 645-649 (2001).
34. Marcen, R. et al. Lumbar bone mineral density in renal transplant patients on neoral and tacrolimus: a four-year prospective study. Transplantation 81, 826-831 (2006).
35. Tang, L. et al. FK506 enhanced osteoblastic differentiation in mesenchymal cells. Cell Biol. Int. 26, 75-84 (2002).
36. Kirino, S. et al. Regulation of bone metabolism in immunosuppressant (FK506)-treated rats. J. Bone Miner. Metab. 22, 554-560 (2004).
37. Patel, S. et al. Prevalence and causes of low bone density and fractures in kidney transplant patients. J. Bone Miner. Res. 16, 1863-1870 (2001).
38. Movsowitz, C., epstein, S., Fallon, M., Ismail, F. & Thomas, S. Cyclosporin-A in vivo produces severe osteopenia in the rat: effect of dose and duration of administration. Endocrinology 123, 2571-2577 (1988).
39. Schlosberg, M. et al. The effect of cyclosporin A administration and its withdrawal on bone mineral metabolism in the rat. Endocrinology 124, 2179-2184 (1989).
40. epstein, S. et al. effect of the interaction of parathyroid hormone and cyclosporine a on bone mineral metabolism in the rat. Calcif. Tissue Int. 68, 240-247 (2001).
41. Rastogi, R., Faugere, M. C., Geng, Z., Bognar, B. & Malluche, H. H. Cyclosporin does not induce bone loss but enhances mineralization in normal and nephrectomized rats. J. Bone Miner. Res. 12 (Suppl. 1), 402 (1997).
42. Briner, v. A., Landmann, J., Brunner, F. P. & Thiel, G. Cyclosporin A-induced transient rise in plasma alkaline phosphatase in kidney transplant patients. Transpl. Int. 6, 99-107 (1993).
43. Bozkaya, G. et al. Impact of calcineurin inhibitors on bone metabolism in primary kidney transplant patients. Transplant. Proc. 40, 151-155 (2008).
44. Joffe, I. et al. Lack of change of cancellous bone volume with short-term use of the new immunosuppressant rapamycin in rats. Calcif. Tissue Int. 53, 45-52 (1993).
45. Bryer, H. P. et al. Azathioprine alone is bone sparing and does not alter cyclosporin A-induced osteopenia in the rat. J. Bone Miner. Res. 10, 132-138 (1995).
46. Dissanayake, I. R. et al. Mycophenolate mofetil: a promising new immunosuppressant that does not cause bone loss in the rat. Transplantation 65, 275-278 (1998).
47. Singha, U. K. et al. Rapamycin inhibits osteoblast proliferation and differentiation in MC3T3-e1 cells and primary mouse bone marrow stromal cells. J. Cell. Biochem. 103, 434-446 (2008).
48. Kneissel, M. et al. everolimus suppresses cancellous bone loss, bone resorption, and cathepsin K expression by osteoclasts. Bone 35, 1144-1156 (2004).
49. Malluche, H. et al. Bone histology in incipient and advanced renal failure. Kidney Int. 9, 355-362 (1976).
50. Bellorin-Font, e., Rojas, e., Carlini, R. G., Suniaga, O. & weisinger, J. R. Bone remodeling after renal transplantation. Kidney Int. Suppl. S125-S128 (2003).
51. Akaberi, S., Lindergard, B., Simonsen, O. & Nyberg, G. Impact of parathyroid hormone on bone density in long-term renal transplant patients with good graft function. Transplantation 82, 749-752 (2006).
52. Bonarek, H. et al. Reduced parathyroid functional mass after successful kidney transplantation. Kidney Int. 56, 642-649 (1999).
53. Parfitt, A. M. Hypercalcemic hyperparathyroidism following renal transplantation: differential diagnosis, management, and implications for cell population control in the parathyroid gland. Miner. Electrolyte Metab. 8, 92-112 (1982).
54. evenepoel, P. et al. Natural history of parathyroid function and calcium metabolism after kidney transplantation: a single-center study. Nephrol. Dial. Transplant. 19, 1281-1287 (2004).
55. Reinhardt, w. et al. Sequential changes of biochemical bone parameters after kidney transplantation. Nephrol. Dial. Transplant. 13, 436-442 (1998).
56. Messa, P. et al. Persistent secondary hyperparathyroidism after renal transplantation. Kidney Int. 54, 1704-1713 (1998).
57. Kruse, A. e., eisenberger, U., Frey, F. J. & Mohaupt, M. G. The calcimimetic cinacalcet normalizes serum calcium in renal transplant patients with persistent hyperparathyroidism. Nephrol. Dial. Transplant. 20, 1311-1314 (2005).
58. Torres, A., Lorenzo, v. & Salido, e. Calcium metabolism and skeletal problems after transplantation. J. Am. Soc. Nephrol. 13, 551-558 (2002).
59. Lewin, e. Involution of the parathyroid glands after renal transplantation. Curr. Opin. Nephrol. Hypertens. 12, 363-371 (2003).
60. Caravaca, F. et al. Are plasma 1,25-dihydroxyvitamin D3 concentrations appropriate after successful kidney transplantation? Nephrol. Dial. Transplant. 13 (Suppl. 3), 91-93 (1998).
61. Drueke, T. B. Primary and secondary uremic hyperparathyroidism: from initial clinical observations to recent findings. Nephrol. Dial. Transplant. 13, 1384-1387 (1998).
62. Borchhardt, K. et al. Low-turnover bone disease in hypercalcemic hyperparathyroidism after kidney transplantation. Am. J. Transplant. 7, 2515-2521 (2007).
63. evenepoel, P. et al. Calcium metabolism in the early posttransplantation period. Clin. J. Am. Soc. Nephrol. 4, 665-672 (2009).
64. Gwinner, w. et al. early calcification of renal allografts detected by protocol biopsies: causes and clinical implications. Am. J. Transplant. 5, 1934-1941 (2005).
65. evenepoel, P., Naesens, M., Claes, K., Kuypers, D. & vanrenterghem, Y. Tertiary 'hyperphosphatoninism' accentuates hypophosphatemia and suppresses calcitriol levels in renal transplant recipients. Am. J. Transplant. 7, 1193-1200 (2007).
66. Green, J. et al. evidence for a PTH-independent humoral mechanism in post-transplant hypophosphatemia and phosphaturia. Kidney Int. 60, 1182-1196 (2001).
67. Bhan, I. et al. Post-transplant hypophosphatemia: Tertiary 'Hyper- Phosphatoninism'? Kidney Int. 70, 1486-1494 (2006).
68. evenepoel, P. et al. Recovery of hyperphosphatoninism and renal phosphorus wasting one year after successful renal transplantation. Clin. J. Am. Soc. Nephrol. 3, 1829-1836 (2008).
69. Serra, A. L., wuhrmann, C. & wuthrich, R. P. Phosphatemic effect of cinacalcet in kidney transplant recipients with persistent hyperparathyroidism. Am. J. Kidney Dis. 52, 1151-1157 (2008).
70. Mann, K. J. et al. Renal denervation enhances the phosphaturic effect of parathyroid hormone. Miner. Electrolyte Metab. 17, 16-20 (1991).
71. Mann, K. J., Dousa, D. M., Kerrigan, R. J., Berndt, T. J. & Knox, F. G. Acute renal denervation decreases tubular phosphate reabsorption. Miner. Electrolyte Metab. 18, 354-358 (1992).
72. Berndt, T. J., Khraibi, A. A. & Knox, F. G. Interaction of the renal nerves and prostaglandins on the phosphaturic response to PTH in phosphate-deprived rats. Am. J. Physiol. 268, R731-R735 (1995).
73. Straub, B. et al. Hyperphosphaturia after kidney transplantation in syngeneic rats: effects on nephrocalcinosis and bone metabolism? Transplant. Proc. 35, 1575-1580 (2003).
74. Gazdar, A. F. & Dammin, G. J. Neural degeneration and regeneration in human renal transplants. N. Engl. J. Med. 283, 222-224 (1970).
75. Sankari, B. et al. Studies on the afferent and efferent renal nerves following autotransplantation of the canine kidney. J. Urol. 148, 206-210 (1992).
76. Amin, H., wall, B. M. & Cooke, C. R. Osteomalacia and secondary hyperparathyroidism after kidney transplantation: Relationship to vitamin D deficiency. Am. J. Med. Sci. 333, 58-62 (2007).
77. Fleseriu, M. & Licata, A. A. Failure of successful renal transplant to produce appropriate levels of 1,25-dihydroxyvitamin D. Osteoporos. Int. 18, 363-368 (2007).
78. Lippuner, K., Casez, J. P., Horber, F. F. & Jaeger, P. effects of deflazacort versus prednisone on bone mass, body composition, and lipid profile: a randomized, double blind study in kidney transplant patients. J. Clin. Endocrinol. Metab. 83, 3795-3802 (1998).
79. Mikuls, T. R., Julian, B. A., Bartolucci, A. & Saag, K. G. Bone mineral density changes within six months of renal transplantation. Transplantation 75, 49-54 (2003).
80. Nam, J. H. et al. Pamidronate and calcitriol trial for the prevention of early bone loss after renal transplantation. Transplant. Proc. 32, 1876 (2000).
81. Brandenburg, v. M. et al. early rapid loss followed by long-term consolidation characterizes the development of lumbar bone mineral density after kidney transplantation. Transplantation 77, 1566-1571 (2004).
82. Pichette, v. et al. Long-term bone loss in kidney transplant recipients: a cross-sectional and longitudinal study. Am. J. Kidney Dis. 28, 105-114 (1996).
83. Cruz, D. N. et al. Parameters of high boneturnover predict bone loss in renal transplant patients: a longitudinal study. Transplantation 72, 83-88 (2001).
84. Josephson, M. A. et al. Calcium and calcitriol prophylaxis attenuates posttransplant bone loss. Transplantation 78, 1233-1236 (2004).
85. wissing, K. M. et al. A controlled study of vitamin D3 to prevent bone loss in renaltransplant patients receiving low doses of steroids. Transplantation 79, 108-115 (2005).
86. el-Agroudy, A. e., el-Husseini, A. A., el-Sayed, M., Mohsen, T. & Ghoneim, M. A. A prospective randomized study for prevention of postrenal transplantation bone loss. Kidney Int. 67, 2039-2045 (2005).
87. Grotz, w. H. et al. Bone fracture and osteodensitometry with dual energy X-ray absorptiometry in kidney transplant recipients. Transplantation 58, 912-915 (1994).
88. Abbott, K. C. et al. Hospitalizations for fractures after renal transplantation in the United States. Ann. Epidemiol. 11, 450-457 (2001).
89. Ball, A. M. et al. Risk of hip fracture among dialysis and renal transplant recipients. JAMA 288, 3014-3018 (2002).
90. Nisbeth, U., Lindh, e., Ljunghall, S., Backman, U. & Fellstrom, B. Fracture frequency after kidney transplantation. Transplant. Proc. 26, 1764 (1994).
91. Chiu, M. Y. et al. Analysis of fracture prevalence in kidney-pancreas allograft recipients. J. Am. Soc. Nephrol. 9, 677-683 (1998).
92. Nisbeth, U., Lindh, e., Ljunghall, S., Backman, U. & Fellstrom, B. Increased fracture rate in diabetes mellitus and females after renal transplantation. Transplantation 67, 1218-1222 (1999).
93. Foley, R. N., Parfrey, P. S. & Sarnak, M. J. epidemiology of cardiovascular disease in chronic renal disease. J. Am. Soc. Nephrol. 9, S16-S23 (1998).
94. Ojo, A. O. et al. Long-term survival in renal transplant recipients with graft function. Kidney Int. 57, 307-313 (2000).
95. Braun, J. et al. electron. beam computed tomography in the evaluation of cardiac calcification in chronic dialysis patients. Am. J. Kidney Dis. 27, 394-401 (1996).
96. Blacher, J., Guerin, A. P., Pannier, B., Marchais, S. J. & London, G. M. Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease. Hypertension 38, 938-942 (2001).
97. Nguyen, P. T. et al. Prevalence and determinants of coronary and aortic calcifications assessed by chest CT in renal transplant recipients. Am. J. Nephrol. 27, 329-335 (2007).
98. Kasiske, B. L. Cardiovascular disease after renal transplantation. Semin. Nephrol. 20, 176-187 (2000).
99. Moe, S. M. et al. Natural history of vascular calcification in dialysis and transplant patients. Nephrol. Dial. Transplant. 19, 2387-2393 (2004).
100. Moe, S. M. vascular calcification and renal osteodystrophy relationship in chronic kidney disease. Eur. J. Clin. Invest. 36 (Suppl. 2), 51-62 (2006).
101. Goodman, w. G. et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N. Engl. J. Med. 342, 1478-1483 (2000).
102. Adragao, T. et al. vascular calcifications and bone turnover in hemodialysis patients. Nephrol. Dial. Transplant. 21 (Suppl. iv), 292 (2006).
103. Barreto, D. v. et al. Association of changes in bone remodeling and coronary calcification in hemodialysis patients: a prospective study. Am. J. Kidney Dis. 52, 1139-1150 (2008).
104. weisinger, J. R., Carlini, R. G., Rojas, e. & Bellorin- Font, e. Bone disease after renal transplantation. Clin. J. Am. Soc. Nephrol. 1, 1300-1313 (2006).
105. Palmer, S. C., McGregor, D. O. & Strippoli, G. F. Interventions for preventing bone disease in kidney transplant recipients. Cochrane Database Syst. Rev. CD005015 (2007).
106. Triponez, F., Clark, O. H., vanrenthergem, Y. & evenepoel, P. Surgical treatment of persistent hyperparathyroidism after renal transplantation. Ann. Surg. 248, 18-30 (2008).
107. ebeling, P. R. Approach to the patient with transplantation-related bone loss. J. Clin. Endocrinol. Metab. 94, 1483-1490 (2009).
108. Bergua, C. et al. effect of cinacalcet on hypercalcemia and bone mineral density in renal transplanted patients with secondary hyperparathyroidism. Transplantation 86, 413-417 (2008).
109. Cho, M. e. et al. Cinacalcet Improves Bone Density in Post Kidney Transplant Hyperparathyroidism. Presented at the American Society of Nephrology Renal week, 2008.
110. Coco, M. et al. Prevention of bone loss in renal transplant recipients: a prospective, randomized trial of intravenous pamidronate. J. Am. Soc. Nephrol. 14, 2669-2676 (2003).
111. Malluche, H. H., Goldstein, D. A. & Massry, S. G. effects of 6 months therapy with 1,25 (OH)2D3 on bone disease of dialysis patients. Contrib. Nephrol. 18, 98-104 (1980).
112. Reeve, J. et al. Anabolic effect of human parathyroid hormone fragment on trabecular bone in involutional osteoporosis: a multicenter trial. Br. Med. J. 280, 1340-1344 (1980).
113. Neer, R. M. et al. effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N. Engl. J. Med. 344, 1434-1441 (2001).
114. Cejka, D. et al. effect of teriparatide on early bone loss after kidney transplantation. Am. J. Transplant. 8, 1864-1870 (2008).